Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

Abstract

BVS implantation for patients with ACS is safe, with outcomes comparable with those of drug-eluting metal stents.

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry

“…Recently, bioresorbable vascular scaffolds (BRS) were introduced, which provide temporary vessel scaffolding with drug delivery capacity but do not carry the limitations of a permanent metallic stent in the long term [8,9]. Prospective studies demonstrated BRS safety and efficacy on selected patients [10][11][12], but some studies have reported increased ST rates [13][14][15][16][17][18][19]. However, data on a large sample of ACS patients are still lacking [15,17,[20][21][22][23][24], and only few studies have evaluated the impact of lesion preparation and postdilatation of BRS [25][26][27].…”

The Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic Review

“…The ABSORB II trial was the only RCT with published data comparing BVS with DES. 7 Studies conducted by Gori et al and Costopoulos et al included a reference group that was treated with DES 8,9 ; the remaining studies did not include a reference group or report on its outcomes.…”

“…8,9 Gori et al included only patients with ACS from May 2013 and June 2013 at 1 institution in Mainz, Germany. Treatment allocation was dependent on scaffold availability during implantation and thus was not randomized.…”

“…10 -17 Four studies studied patients with acute coronary syndrome (ACS) exclusively, 8,13,15,16 and the remaining studies included stable or mixed patient populations. Outcomes of the 11 included studies are summarized in Tables 3 and 4.…”

“…Planned non-target-lesion revascularizations (nTLR) were included in the MACE definition; 6 of the 16 MACE in the BVS group were planned nTLR, compared with 9 of the 16 MACE in the DES group. 8 Costopoulos et al included all patients who received a BVS from May 2012 to August 2013 at 2 centers in Milan, Italy. Lesions of this study had an average Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) score of 17.2 ± 9.8.…”